The shares of the pharmaceutical company, specializing in developing and marketing generic formulations, biotechnology products, and APIs globally, jumped upto 3 percent upon launching a New Drug Application from the U.S. FDA approval.
Price action
With a market capitalization of Rs. 93,143.48 Crores on Monday, the shares of Lupin Limited rose by upto 2.6 percent after making a high of Rs. 2081.95 compared to its previous closing price of Rs. 2028.90.
What Happened
Lupin Limited engaged in developing and marketing generic formulations, biotechnology products, and APIs globally, has launched Rivaroxaban Tablets USP, 2.5 mg, in the U.S. following FDA approval.
The tablets are bioequivalent to Janssen Pharmaceuticals’ Xarelto 2.5 mg and are used to reduce the risk of major cardiovascular events in patients with coronary artery disease (CAD) and to lower the risk of major blood clot events in patients with peripheral artery disease (PAD), particularly those who have recently undergone lower extremity revascularization due to symptomatic PAD and the Rivaroxaban 2.5 mg had U.S. sales of approximately $446 million in 2025.
Lupin at Glance
The company specializes in generics, biotechnology, and APIs it focuses on providing high-quality, affordable medicines across various therapeutic areas, including cardiovascular, oncology, and respiratory.
Lupin is a global pharmaceutical leader with a presence in over 100 countries. It ranks 12th globally in generics by sales and is the largest generic company in the US, Australia, South Africa, and more.
With annual sales of $2.4 billion and 23,000+ employees, Lupin focuses on sustainable growth and innovation, operating 15 manufacturing sites and 7 R&D sites globally, and has planned to set up 58MW Renewable energy capacity by FY25.
Key Business Developments (Q3FY25)
The company has acquired Eli Lilly’s Huminsulin to enhance India’s Diabetes Portfolio, and they have partnered to commercialize NaMuscla in Argentina & Colombia, and have filed Ranibizumab for European Union (EU) markets.
Also Read:
Financials
The company’s revenue rose by 11.38 percent from Rs. 5,226.78 crore to Rs. 5,821.42 crore in Q3FY24-25. Meanwhile, Net profit rose from Rs. 613.12 crores to Rs. 855.16 crore during the same period.
Written by Sridhar J
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
